Tvardi Therapeutics, Inc.
TVRD•NASDAQ•Healthcare•Biotechnology

About Tvardi Therapeutics

Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting STAT3 to treat fibrosis-driven diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 2 clinical development stage for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI-109, an oral, small molecule STAT3 inhibitor which is in pre-clinical stage. Tvardi Therapeutics, Inc. was founded in 2017 and is based in Sugar Land, Texas.

Company Information

SectorHealthcare
IndustryBiotechnology
CEOImran Alibhai
Founded2017
Employees12
CountryUnited States
Fiscal YearJanuary - December

Stock Details

ExchangeNASDAQ (NASDAQ)
CurrencyUSD - USD
TypeStock
SubtypeCommon Stock

Contact Information

Websitetvarditherapeutics.com
Phone713 489 8654
Address
3 Sugar Creek Center Boulevard, Suite 525 Sugar Land, Texas 77478 United States

Corporate Identifiers

CIK0001742947
CUSIP140755307
ISINUS1407553072
EIN82-3784554

Leadership Team & Key Executives

Dr. Imran Alibhai Ph.D.
Chief Executive Officer and Director
Wallace Hall
Founder, President and Director
Dan Conn J.D., M.B.A.
Chief Financial Officer
Dr. John Kauh M.D.
Chief Medical Officer
David J. Tweardy M.D.
Co-Founder and Scientific Advisory Board Member
Dr. Ronald A. DePinho M.D.
Co-Founder and Chairman of Scientific Advisory Board
Dr. Michael T. Lewis Ph.D.
Co-Founder and Scientific Advisory Board Member
Dr. Jeffrey Larson DABT, Ph.D.
Senior Vice President of Research & Development
Stephen O'Brien CPA
Vice President of Finance and Corporate Controller
Dr. Yixin Chen Ph.D.
Vice President of CMC